<DOC>
	<DOC>NCT02394782</DOC>
	<brief_summary>This is a 24-month, observational, prospective, multinational, multicenter study to determine the relationship between the relapse (percentage of relapse free subjects) and adherence in subjects diagnosed with RRMS treated with Rebif (interferon beta-1a) using the RebiSmart®2.0 and MSdialog™.</brief_summary>
	<brief_title>Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Diagnosed with RRMS according to McDonald criteria 2010 Relapse free within 30 days before Baseline data collection Treatment with Rebif for 6 months or more prior to informed consent Already using RebiSmart®2.0 + MSdialog™ for patient reported outcome (PRO) assessments (at least once prior to informed consent) Females of childbearing potential must be willing to use appropriate contraception for the duration of the study EDSS score less than (&lt;) 6 Written informed consent obtained prior to any protocolrequired data collection Participation in other studies within 30 days before Baseline Female who is pregnant or breast feeding Significant psychiatric symptoms that, in the opinion of the Investigator, would impact subject ability to comply with treatment (as per standard clinical practice) Any contraindication for Interferon (IFN) beta1a therapy as per Summary of Product Characteristics (SPC) Administration of any Multiple Sclerosis (MS) therapy, other than Rebif, within 6 months prior to informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Multiple sclerosis, relapsing-remitting</keyword>
	<keyword>Rebif</keyword>
	<keyword>Interferon beta-1a</keyword>
	<keyword>RebiSmart®2.0</keyword>
	<keyword>MSdialog™</keyword>
</DOC>